{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:13:38Z","timestamp":1791825218704,"version":"4.3.4"},"posted":{"date-parts":[[2024,1,16]]},"group-title":"In Review","reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,1,5]]},"abstract":"<title>Abstract<\/title>\n        <p>We retrospectively analyzed 609 chronic lymphocytic leukemia (CLL) patients treated with BTK inhibitors (BTKis) at Dana-Farber Cancer Institute from 2014 to 2022. Among them, 85 underwent next-generation sequencing (NGS) during or after BTKi therapy (ibrutinib, 64; acalabrutinib, 13; pirtobrutinib, 7; vecabrutinib, 1). Patients with NGS at progression (N=36, PD group) showed more 17p deletion, complex karyotype, and previous treatments including BTKi, compared to ongoing responders (N=49, NP group). 216 variants were found in 57 genes across both groups, with more variants in the PD group (158 variants, 70.3% pathogenic, P&lt;0.001). The PD group had a higher incidence of pathogenic variants (70.3%, P&lt;0.001), including 32 <italic>BTK<\/italic> (<italic>BTK<\/italic> C481S\/F\/R\/Y, L528W, and T474I\/L) and 4 <italic>PLCG2<\/italic>mutations. Notably, a high VAF L528W mutation was found in a first line ibrutinib-resistant patient. <italic>TP53<\/italic>, <italic>SF3B1<\/italic>, and <italic>NOTCH2<\/italic>mutations were also significantly more prevalent in the PD group (P&lt;0.01, P&lt;0.05, P&lt;0.05). Additionally, <italic>MAPK<\/italic> pathway gene mutations trended more common and had higher VAFs in the PD group (P=0.041). T474 mutations were found in 4 of 6 patients progressing on pirtobrutinib, and <italic>BTK<\/italic> L528W mutation can arise with both covalent and non-covalent BTKi therapy. These results also suggest that <italic>RAS\/RAF\/MAPK<\/italic> pathway mutations may contribute to BTKi resistance.<\/p>","DOI":"10.21203\/rs.3.rs-3837426\/v1","type":"posted-content","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T19:29:57Z","timestamp":1705433397000},"source":"Crossref","is-referenced-by-count":9,"title":["Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer","family":"Brown","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-3285","authenticated-orcid":false,"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishath","family":"Naeem","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Shupe","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Fardoun","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew","family":"Davids","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"13","key":"ref1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach J","year":"2017","unstructured":"Woyach J, Ruppert AS Daphne, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017;35(13):1437\u20131443. doi: 10.1200\/JCO.2016.70.2282. Epub 2017 Feb 13.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach JA","year":"2014","unstructured":"Woyach J. A., Furman R. R., Liu T. M., Ozer H. G., Zapatka M., Ruppert A. S., et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286\u201394.","journal-title":"N Engl J Med"},{"issue":"10277","key":"ref3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato AR","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM Woyach JA, et al., Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901. doi:10.1016\/S0140-6736(21)00224-5","journal-title":"Lancet"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance","volume":"7","author":"Naeem A","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, et al. Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance. Blood Adv. 2023;7(9):1929\u20131943. doi:10.1182\/bloodadvances.2022008447","journal-title":"Blood Adv"},{"issue":"8","key":"ref5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors","volume":"386","author":"Wang E","year":"2022","unstructured":"Wang E, Mi X, Tompson MC, Montoya S, Notti RQ, Afaghani J, et al., Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med. 2022;386(8):735\u2013743. doi: 10.1056\/NEJMoa2114110.","journal-title":"N Engl J Med"},{"key":"ref6","first-page":"S146","article-title":"Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Phase I\/II BRUIN Study","volume":"387846","author":"Jennifer R","year":"2023","unstructured":"Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady Tantawy, Samuel Clark McNeely, et al., Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Phase I\/II BRUIN Study. EHA Library. 2023; 387846; S146","journal-title":"EHA Library"},{"issue":"13","key":"ref7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.2020006783","article-title":"Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies","volume":"138","author":"Stephens DM","year":"2021","unstructured":"Stephens DM and Byrd JC. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021;138(13):1099\u20131109. doi: 10.1182\/blood.2020006783.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies","volume":"10","author":"Ondrisova L","year":"2020","unstructured":"Ondrisova L and Mraz M. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. Front Oncol. 2020;10:591577. doi: 10.3389\/fonc.2020.591577.","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna R","year":"2019","unstructured":"Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 2019;125:559\u2013574. doi: 10.1002\/cncr.31831","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies","volume":"18","author":"Kluk MJ","year":"2016","unstructured":"Kluk MJ, Lindsley RC, Aster JC, Lindeman NI, Szeto D, Hall D, et al. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. J Mol Diagn 2016;18:507\u2013515.","journal-title":"J Mol Diagn"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-touse software \u2019EZR\u2019 for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-touse software \u2019EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u2013458.","journal-title":"Bone Marrow Transpl"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/1078-0432.CCR-15-2921","article-title":"Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia","volume":"23","author":"Amin NA","year":"2017","unstructured":"Amin NA, Balasubramanian S, Saiya-Cork K, Shedden K, Hu N and Malek SN. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia. Clin. Cancer Res. 2017; 23:1049\u20131059.","journal-title":"Clin. Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger JA","year":"2016","unstructured":"Burger JA, Landau,DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al., Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. doi: 10.1038\/ncomms11589.","journal-title":"Nat Commun."},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau DA","year":"2017","unstructured":"Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8(1):2185.","journal-title":"Nat Commun"},{"issue":"12","key":"ref15","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio S","year":"2023","unstructured":"Bonfiglio S, Sutton LA, Ljungstr\u00f6m V, Capasso A, Pandzic T, Westr\u00f6m S, et al., BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023;7(12):2794\u20132806. doi:10.1182\/bloodadvances.2022008821","journal-title":"Blood Adv"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.22.00269","article-title":"Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia","volume":"41","author":"Lampson BL","year":"2023","unstructured":"Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petr\u00e1\u010dkov\u00e1 A, Wang Z, et al. Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia. J Clin Oncol. 2023;41(5):1116\u20131128. doi: 10.1200\/JCO.22.00269. Epub 2022 Oct 31. PMID: 36315919.","journal-title":"J Clin Oncol"},{"issue":"6892","key":"ref17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies H","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u2013954. doi: 10.1038\/nature00766.","journal-title":"Nature"},{"key":"ref18","author":"Lohr JG","year":"2014","unstructured":"Lohr JG, Stojanov P,1 Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell 2014;25:91\u2013101."},{"issue":"7666","key":"ref19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao Z","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666):234\u2013238. doi: 10.1038\/nature23291.","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fonc.2019.01088","article-title":"A Comparative Analysis of Individual RAS Mutations in Cancer Biology","volume":"9","author":"Mu\u00f1oz-Maldonado C","year":"2019","unstructured":"Mu\u00f1oz-Maldonado C, Zimmer Y, Medov\u00e1 M. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Front Oncol. 2019;9:1088. doi: 10.3389\/fonc.2019.01088.","journal-title":"Front Oncol"},{"issue":"11","key":"ref21","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/cancers13112541","article-title":"KRAS G12C Mutations in NSCLC: From Target to Resistance","volume":"13","author":"Addeo A","year":"2021","unstructured":"Addeo A, Banna GL, Friedlaender A. KRAS G12C Mutations in NSCLC: From Target to Resistance. Cancers (Basel). 2021;13(11):2541. doi: 10.3390\/cancers13112541.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood.2020006765","article-title":"Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia","volume":"138","author":"Murali I","year":"2021","unstructured":"Murali I, Kasar S, Naeem A, Tyekucheva S, Khalsa JK, Thrash EM, et al. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021;138(1):44\u201356. doi: 10.1182\/blood.2020006765.","journal-title":"Blood"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood.2021015132","article-title":"Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients","volume":"140","author":"Black GS","year":"2022","unstructured":"Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, et al. Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Blood. 2022;140(4):401\u2013405. doi: 10.1182\/blood.2021015132.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283372","article-title":"Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies","volume":"14","author":"Woolston DW","year":"2023","unstructured":"Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, et al. Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies. Haematologica. Published online September 14, 2023. doi:10.3324\/haematol.2023.283372","journal-title":"Haematologica. Published online September"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.17502","article-title":"Screening and monitoring of the BTK C481S mutation in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukaemia during ibrutinib therapy","volume":"194","author":"B\u00f6d\u00f6r C","year":"2021","unstructured":"B\u00f6d\u00f6r C, Kotmayer L, L\u00e1szl\u00f3 T, Tak\u00e1cs F, Barna G, Kiss R, et al. Screening and monitoring of the BTK C481S mutation in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukaemia during ibrutinib therapy. Br J Haematol. 2021;194:355\u201364.","journal-title":"Br J Haematol"},{"issue":"16","key":"ref26","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1158\/1078-0432.CCR-22-3887","article-title":"B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy","volume":"29","author":"Woyach JA","year":"2023","unstructured":"Woyach JA, Ghia P, Byrd JC., Ahn IE., Moreno C, O'Brien SM, et al. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clin Cancer Res. 2023;29(16):3065\u20133073. doi:10.1158\/1078-0432.CCR-22-3887","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"386","author":"Wang E","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors. N Engl J Med 2022; 386:735\u2013743","journal-title":"N Engl J Med"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn IE","year":"2017","unstructured":"Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017;129 (11): 1469\u20131479.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations","volume":"383","author":"Ahn IE","year":"2020","unstructured":"Ahn IE, Tian X, Wiestner A. Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. N Engl J Med 2020; 383:498\u2013500","journal-title":"N Engl J Med"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown JR","year":"2018","unstructured":"Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL. Leukemia. 2018;32(1):83\u201391.","journal-title":"Leukemia"},{"issue":"24","key":"ref31","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-19-1009","article-title":"Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"25","author":"Papa B","year":"2019","unstructured":"Del Papa B, Baldoni S, Dorillo E, De Falco F, Rompietti C, Cecchini D, et al,. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2019;25 (24): 7540\u20137553.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref32","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3109\/10428194.2015.1113276","article-title":"CD79B limits response of diffuse large B cell lymphoma to ibrutinib","volume":"57","author":"Kim JH","year":"2016","unstructured":"Kim JH, Kim WS, Ryu K, Kim SJ, Park C. CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leuk Lymphoma. 2016;57(6):1413\u201322. doi: 10.3109\/10428194.2015.1113276. Epub 2015 Dec 24.","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"ref33","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2022-169574","article-title":"Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma","volume":"140","author":"Kersy O","year":"2022","unstructured":"Kersy O, Salmon-Divon M, da Silva MG, Moita AF, Cabecadas J, Klener P Jr, et al. Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma. Blood. 2022;140 (Supplement 1): 3109\u20133110.","journal-title":"Blood"},{"issue":"6","key":"ref34","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3324\/haematol.2018.212571","article-title":"Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia","volume":"106","author":"Heerema NA","year":"2021","unstructured":"Heerema NA, Muthusamy N, Zhao Q, Ruppert AS, Breidenbach H, Andritsos LA, et al. Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. Haematologica. 2021;106(6):1608\u20131615. doi: 10.3324\/haematol.2018.212571.","journal-title":"Haematologica"},{"issue":"23","key":"ref35","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1182\/blood.2020010536","article-title":"The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib","volume":"138","author":"Kittai AS","year":"2021","unstructured":"Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K,et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138(23):2372\u20132382. doi: 10.1182\/blood.2020010536.","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019634","article-title":"High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations Blood. 2023;blood.2023019634","author":"F\u00fcrstenau M","unstructured":"F\u00fcrstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AMF, Dubois J, et al. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations Blood. 2023;blood.2023019634. doi: 10.1182\/blood.2023019634. Online ahead of print."},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson BL","year":"2018","unstructured":"Lampson BL & Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018;11(3):185\u2013194.","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(03)01225-7","article-title":"Chromosome arm 8p and cancer: a fragile hypothesis doi: 10.1016\/s1470-2045(03)01225-7","volume":"4","author":"Birnbaum D","year":"2003","unstructured":"Birnbaum D, Ad\u00e9la\u00efde J, Popovici C, Charafe-Jauffret E, Mozziconacci MJ, Chaffanet M. Chromosome arm 8p and cancer: a fragile hypothesis doi: 10.1016\/s1470-2045(03)01225-7. Lancet Oncol. 2003;4(10):639\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"ref39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-09-1423","article-title":"Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer","volume":"16","author":"El Gammal AT","year":"2010","unstructured":"El Gammal AT, Br\u00fcchmann M, Zustin J, Isbarn H, Hellwinkel OJ, K\u00f6llermann J, et al., Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16(1):56\u201364. doi: 10.1158\/1078-0432.CCR-09-1423. Epub 2009 Dec 22. PMID: 20028754","journal-title":"Clin Cancer Res"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3837426\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3837426\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T15:51:18Z","timestamp":1707148278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3837426\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":39,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3837426\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,1,16]]},"subtype":"preprint"}}